Tocilizumab
Tocilizumab
Definition
A recombinant, humanized IgG1 monoclonal antibody directed against the interleukin-6 receptor (IL-6R) with immunosuppressant activity. Tocilizumab targets and binds to both the soluble form of IL-6R (sIL-6R) and the membrane-bound form (mIL-6R), thereby blocking the binding of IL-6 to its receptor. This prevents IL-6-mediated signaling. IL-6, a pro-inflammatory cytokine that plays an important role in the regulation of the immune response, is overproduced in autoimmune disorders, certain types of cancers and possibly various other inflammatory conditions.
Also known as Actemra, IL-6 receptor monoclonal antibodies: tocilizumab, Immunoglobulin G1, Anti-(Human Interleukin 6 Receptor) (Human-Mouse Monoclonal MRA Heavy Chain), Disulfide with Human-Mouse Monoclonal MRA Kappa-Chain, Dimer, MRA, R-1569, RoActemra, TOCILIZUMAB — per NCIT
Also identified as
- ATC L04AC07 per RXNORM
- NCIT NCIT:C84217 per NCIT
- SCTID 444648007 per RXNORM
- SCTID 444649004 per RXNORM
- UNII I031V2H011 per RXNORM
Indications
| Disease | Relation | Source |
|---|---|---|
| Cytokine release syndrome | may treat | MEDRT · Public domain (U.S. Government work) |
| Juvenile idiopathic arthritis | may treat | MEDRT · Public domain (U.S. Government work) |
| Rheumatoid arthritis | may treat | MEDRT · Public domain (U.S. Government work) |
Organ Effects
| Organ | Side effect / interaction | Source |
|---|---|---|
| Bone element | may treat a disease of this organ | DERIVED · CC BY 4.0 |
| Musculoskeletal system | may treat a disease of this organ | DERIVED · CC BY 4.0 |
| Skeletal joint | may treat a disease of this organ | DERIVED · CC BY 4.0 |
3 entries above are marked DERIVED: Atlas Médico inferred them by combining two sourced claims, and no source asserts these links directly. Treat them as a navigation aid, not as a clinical statement.